BACKGROUND: The overall impact of influenza virus infection in immunocompromised patients is largely unknown. Antigenic drift and genetic variations during prolonged influenza infection have been demonstrated. In this report we describe a multidrug-resistant H3N2 influenza virus isolated from an immunocompromised patient after 5 days of therapy. METHODS: Multiple nasal wash samples were collected from an infected patient, and viral isolates were characterized. Sensitivity to antiviral agents was evaluated. Fitness and transmissibility were assessed in ferrets and tissue culture. RESULTS: An in-frame 4-amino acid deletion emerged in the neuraminidase (NA) gene of an H3N2 virus after 5 days of oseltamivir therapy. No other changes in the NA or hemagglutinin genes were noted. Drug sensitivity assays revealed resistance to oseltamivir (>10-fold increase in 50% inhibitory concentration [IC(50)]) and reduction in sensitivity to zanamivir (3-7-fold increase in IC(50) or 50% effective concentration). No change in fitness or transmissibility was observed. CONCLUSIONS: An in-frame NA gene deletion was rapidly selected for in an immunocompromised patient, resulting in decreased sensitivity of the isolate to available NA inhibitors without a change in fitness or transmissibility. This finding has implications for our understanding of the emergence of antiviral resistance and treatment of patients with influenza A infection, especially those who are immunocompromised.
BACKGROUND: The overall impact of influenza virus infection in immunocompromised patients is largely unknown. Antigenic drift and genetic variations during prolonged influenza infection have been demonstrated. In this report we describe a multidrug-resistant H3N2influenza virus isolated from an immunocompromised patient after 5 days of therapy. METHODS: Multiple nasal wash samples were collected from an infected patient, and viral isolates were characterized. Sensitivity to antiviral agents was evaluated. Fitness and transmissibility were assessed in ferrets and tissue culture. RESULTS: An in-frame 4-amino acid deletion emerged in the neuraminidase (NA) gene of an H3N2 virus after 5 days of oseltamivir therapy. No other changes in the NA or hemagglutinin genes were noted. Drug sensitivity assays revealed resistance to oseltamivir (>10-fold increase in 50% inhibitory concentration [IC(50)]) and reduction in sensitivity to zanamivir (3-7-fold increase in IC(50) or 50% effective concentration). No change in fitness or transmissibility was observed. CONCLUSIONS: An in-frame NA gene deletion was rapidly selected for in an immunocompromised patient, resulting in decreased sensitivity of the isolate to available NA inhibitors without a change in fitness or transmissibility. This finding has implications for our understanding of the emergence of antiviral resistance and treatment of patients with influenza A infection, especially those who are immunocompromised.
Authors: A E Krafft; K L Russell; A W Hawksworth; S McCall; M Irvine; L T Daum; J L Connoly; A H Reid; J C Gaydos; J K Taubenberger Journal: J Clin Microbiol Date: 2005-04 Impact factor: 5.948
Authors: H M Yousuf; J Englund; R Couch; K Rolston; M Luna; J Goodrich; V Lewis; N Q Mirza; M Andreeff; C Koller; L Elting; G P Bodey; E Whimbey Journal: Clin Infect Dis Date: 1997-06 Impact factor: 9.079
Authors: Rick A Bright; Marie-jo Medina; Xiyan Xu; Gilda Perez-Oronoz; Teresa R Wallis; Xiaohong M Davis; Laura Povinelli; Nancy J Cox; Alexander I Klimov Journal: Lancet Date: 2005-09-22 Impact factor: 79.321
Authors: Elodie Ghedin; Edward C Holmes; Jay V DePasse; Lady Tatiana Pinilla; Adam Fitch; Marie-Eve Hamelin; Jesse Papenburg; Guy Boivin Journal: J Infect Dis Date: 2012-09-10 Impact factor: 5.226
Authors: Won-Young Kim; Gee Young Suh; Jin Won Huh; Sung-Han Kim; Min-ju Kim; Yun Seong Kim; Hye-Ryoun Kim; Yon Ju Ryu; Min Soo Han; Young Gwan Ko; Gyu Rak Chon; Kwan Ho Lee; Sang-Ho Choi; Sang-Bum Hong Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Ashley N Brown; James J McSharry; Qingmei Weng; Jonathan R Adams; Robert Kulawy; George L Drusano Journal: Antimicrob Agents Chemother Date: 2011-01-24 Impact factor: 5.191
Authors: Bin Zhou; Victoria A Meliopoulos; Wei Wang; Xudong Lin; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Stacey Schultz-Cherry; David E Wentworth Journal: J Virol Date: 2016-09-12 Impact factor: 5.103
Authors: Alireza Eshaghi; Sarah Shalhoub; Paul Rosenfeld; Aimin Li; Rachel R Higgins; Peter J Stogios; Alexei Savchenko; Nathalie Bastien; Yan Li; Coleman Rotstein; Jonathan B Gubbay Journal: Antimicrob Agents Chemother Date: 2014-09-22 Impact factor: 5.191